跳至主要内容
临床试验/NCT07012785
NCT07012785尚未招募不适用

Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection

Zhongda Hospital1 个研究点 分布在 1 个国家目标入组 208 人开始时间: 2025年6月最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
208
试验地点
1
主要终点
H. Pylori eradication rate

研究概览

简要总结

To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18-70 years, regardless of gender;
  • Positive 13C/14C urea breath test result;
  • No previous history of H. pylori eradication treatment;
  • Agreement to participate in this study and signing of the informed consent form.

排除标准

  • History of ≥ 1 instance of failed H. pylori eradication;
  • Use of antibiotics (including antibacterial traditional Chinese medicines), nonsteroidal anti-inflammatory drugs (NSAIDS), bismuth agents, H2 receptor antagonists (H2RAs), proton-pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CAB) within 4 weeks before treatment;
  • Plans to conceive, pregnancy, or breastfeeding;
  • Severe liver, kidney, or cardiovascular diseases; malignancies; and alcoholism;
  • Allergies to the drugs used in this study or a history of penicillin allergy;
  • The inability to correctly express one's symptoms and wishes, such as inability due to mental illness or severe neurosis.

研究组 & 干预措施

Control Group

Active Comparator

干预措施: Bismuth quadruple therapy (Drug)

Experimental group

Experimental

干预措施: Saccharomyces boulardii (Drug)

结局指标

主要结局

H. Pylori eradication rate

时间窗: 7 days

次要结局

未报告次要终点

研究者

发起方
Zhongda Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Chen Lu

Director

Zhongda Hospital

研究点 (1)

Loading locations...

相似试验